NIKI Stock Forecast: Niki Biosolutions, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 9 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Niki Biosolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (65): Sales and profits are climbing, and climbing faster than before.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NIKI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NIKI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2022 | HC Wainwright & Co. | Initiates | Buy | $8.00 |
| 2 Apr 2019 | China Renaissance | Initiates | Buy | $22 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
NIKI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NIKI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Niki Biosolutions, Inc. returned −88.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NIKI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- —
Cheaper than 97% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −17.1%
- Return on assets
- −10.0%
- Dividend yield
- —
Higher than 33% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Niki Biosolutions, Inc. has a market value of $5.2M.
Niki Biosolutions, Inc. employs 1 people.
Data provided by Twelve Data
NIKI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NIKI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Niki Biosolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NIKI
How does Ticker Nerd's model rank NIKI?
As at 21 Nov 2026, Niki Biosolutions, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (65 of 100).
What is the NIKI stock forecast for 2030?
No analyst covering Niki Biosolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NIKI are extrapolating price history, which says nothing about the business.
How has NIKI stock performed over the past year?
Niki Biosolutions, Inc. returned -88.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Niki Biosolutions, Inc. do?
Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease.
About Niki Biosolutions, Inc.
Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease. The company also works on additional therapeutic assets targeting unmet medical needs across cancer and infectious disease areas. Based in Princeton, New Jersey, Niki BioSolutions operates through subsidiaries and maintains a product portfolio centered on drug development and translational research. Its role in the financial market reflects that of a specialized biotechnology issuer tied to early-stage clinical progress and pipeline advancement.
CEO Mr. Chung Yuen Huen · 1 employees · United States · https://www.aptorumgroup.com